Emerging Biomarker Strategies for Lysosomal Storage Diseases
This interactive module covers the historical, current, and future use of biomarkers to diagnose, treat, and monitor patients with Lysosomal Storage Diseases, or LSDs. Each of the 3 clinical cases involving an LSD features unexpected twists or curveballs. Learn more about the use of biomarkers in GD (Gaucher disease), MPS II (Mucopolysaccharidosis type II), and MLD (Metachromatic leukodystrophy).
This site uses cookies. By continuing to use this website, you agree to their use. For details, please check our Privacy Policy.